Emami Limited
NSE: EMAMILTDPersonal Care
Share price
₹367.25
-2.18% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
68
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹16,159 Cr
P/E ratio
21.3
P/B ratio
5.5
ROCE
28.1%
ROE
26.2%
Dividend yield
2.7%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 2.8% over the past year, and 11.5% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 28.0% to 24.3% over the last four years.
Whether it grew faster than its sector
It grew 11.5% a year against a sector median of 9.9% — 1.5 percentage points faster.
Room to re-rate, or risk of de-rating
At 21.3× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 35.9×, across 5 companies. It is against its own five-year median of 30.8×, the 4th percentile of its own range.
Whether growth justifies the valuation
Priced at 4.3 times its growth rate, on earnings growth of 5%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Emami Limited — this one | 5%/yr | 21.3× | ₹4.3 |
| Godrej Consumer Products | 5%/yr | 42.5× | ₹8.5 |
| Dabur India | 4%/yr | 33.6× | ₹8.4 |
| Cupid Limited | — | 348.8× | — |
| Colgate-Palmolive India | 8%/yr | 34.8× | ₹4.3 |
| Gillette India Limited | 31%/yr | 35.9× | ₹1.2 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Personal Care), it ranks 6 of 10 on returns, 5 of 10 on growth, 5 of 10 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 28.1% on capital, ahead of 40% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹3869 crore of cash from the business, spent ₹613 crore on plant and equipment, and returned ₹2627 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 131 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 0 days for its cash to waiting 21 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 9 checks clear · 67%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Sales up 15% but profit down 15% as the tax rate normalised and input costs rose
Announced 4 Aug 2026 · Consolidated · Unaudited
Revenue
₹1,039 Cr
Revenue vs last year
+15.0%
Revenue vs last quarter
+12.3%
Net profit
₹139 Cr
Profit vs last year
-15.3%
Profit vs last quarter
-2.8%
Net margin
13.4%
EPS
₹3.15
Earnings call transcript · 4 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹16,159 Cr
- Prev close
- ₹367.25
- 52w High
- ₹556
- 52w Low
- ₹361
- Enterprise value
- ₹15,801 Cr
- Beta
- 0.7
- Price CAGR 1y
- -31.0%
- Price CAGR 3y
- -10.0%
- Price CAGR 5y
- -7.0%
- Price CAGR 10y
- -4.0%
Ratios
- Return on assets
- 20.2%
- PEG ratio
- 4.2
- P/E ratio
- 21.3
- P/B ratio
- 5.5
- EV / EBITDA
- 16.9
- Industry P/E
- 34.7
- ROCE
- 28.1%
- ROCE 5y average
- 30.2%
- ROE
- 26.2%
- Debt / Equity
- 0.1
- Interest coverage
- 77.9
- Dividend yield
- 2.7%
- ROE 3y average
- 28.0%
- ROE last year
- 26.0%
Annual P&L
- Annual revenue
- ₹3,780 Cr
- Annual profit
- ₹775 Cr
- Operating margin
- 25.0%
- Net profit margin
- 20.5%
- EBITDA margin
- 25.4%
- Sales growth 3y
- 3.5%
- Sales growth 5y
- 5.6%
- Profit growth 3y
- 5.0%
- Profit growth 5y
- 11.0%
- EPS
- ₹17.8
- Sales growth TTM
- 3.0%
- Profit growth TTM
- -7.0%
- Dividend payout
- 56.0%
Quarter P&L
- Sales latest quarter
- ₹1,039 Cr
- Profit latest quarter
- ₹139 Cr
- YoY quarterly sales growth
- 14.9%
- YoY quarterly profit growth
- -15.2%
- OPM latest quarter
- 21.6%
Balance Sheet
- Book Value
- ₹66.5
- Face Value
- ₹1.0
- Total debt
- ₹162 Cr
- Total cash
- ₹410 Cr
- Borrowings
- ₹162 Cr
- Reserves / Equity
- 65.5
Cash Flow
- Operating cash flow
- ₹801 Cr
- Free cash flow
- ₹770 Cr
- FCF yield
- 4.7%
- Net cash flow
- ₹72 Cr
Shareholding
- Promoter holding
- 54.8%
- FII holding
- 7.9%
- DII holding
- 27.0%
- Public holding
- 10.3%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Godrej Consumer | 865.55 | 42.7 | 88,572 | 2.31 | 504.5 | 10.6 | 4,225.5 | 15.4 | 18.8 |
| Dabur India | 383.55 | 34.3 | 68,040 | 2.15 | 586.2 | 15.0 | 3,764.4 | 10.6 | 20.3 |
| Colgate-Palmoliv | 1,757.40 | 34.9 | 47,799 | 2.73 | 343.1 | 7.8 | 1,603.3 | 11.8 | 108.0 |
| Cupid | 343.95 | 336.6 | 46,250 | 0.00 | 44.2 | 194.0 | 157.0 | 142.5 | 33.9 |
| Gillette India | 7,223.50 | 35.2 | 23,541 | 2.49 | 159.5 | 9.4 | 783.0 | 10.8 | 90.7 |
| P & G Hygiene | 6,921.00 | 28.4 | 22,466 | 3.32 | 126.3 | -34.3 | 891.5 | -4.9 | 157.2 |
| Emami | 375.45 | 21.6 | 16,388 | 2.66 | 138.9 | -16.4 | 1,039.2 | 14.9 | 28.1 |
| Median | 454.55 | 38.2 | 15,971 | 0.34 | 90.5 | 15.0 | 756.0 | 15.4 | 30.2 |
Competes with: Bajaj Consumer Care Limited, Colgate-Palmolive India, Cupid Limited, Dabur India, Gillette India Limited, Godrej Consumer Products, Honasa Consumer Limited, JHS Svendgaard Laboratories Limited, Procter & Gamble Hygiene and Health Care Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 826 | 865 | 996 | 891 | 906 | 891 | 1,049 | 963 | 904 | 799 | 1,152 | 925 | 1,039 |
| Expenses | 636 | 632 | 682 | 682 | 692 | 645 | 715 | 744 | 692 | 622 | 768 | 739 | 815 |
| Material Cost | 162 | 164 | 200 | 211 | 181 | 215 | |||||||
| Change in Inventories | 18 | 4.33 | -68 | 44 | -37 | 26 | |||||||
| Purchases of Stock-in-Trade | 148 | 109 | 99 | 83 | 148 | 115 | |||||||
| Employee Cost | 111 | 119 | 121 | 121 | 117 | 136 | |||||||
| Other Expenses | 305 | 294 | 267 | 308 | 330 | 322 | |||||||
| Operating Profit | 190 | 233 | 314 | 209 | 214 | 246 | 334 | 219 | 212 | 177 | 384 | 186 | 225 |
| OPM % | 23 | 27 | 32 | 24 | 24 | 28 | 32 | 23 | 23 | 22 | 33 | 20 | 22 |
| Other Income | 8 | 11 | 11 | 11 | 10 | 22 | 15 | 21 | 22 | 21 | 9 | 23 | 18 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | -10 | 0 | 0 | |||||||
| Interest | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 6 |
| Depreciation | 46 | 46 | 46 | 48 | 44 | 45 | 46 | 44 | 44 | 45 | 45 | 42 | 43 |
| Profit before tax | 150 | 196 | 276 | 169 | 178 | 220 | 301 | 194 | 187 | 150 | 345 | 164 | 195 |
| Tax % | 9 | 8 | 6 | 13 | 16 | 4 | 7 | 16 | 12 | 1 | 7 | 13 | 29 |
| Net Profit | 137 | 180 | 261 | 147 | 151 | 211 | 279 | 162 | 164 | 148 | 319 | 143 | 139 |
| EPS in Rs | 3.14 | 4.09 | 5.92 | 3.41 | 3.50 | 4.87 | 6.39 | 3.72 | 3.76 | 3.40 | 7.32 | 3.28 | 3.15 |
| Diluted EPS in Rs | 3.72 | 3.76 | 3.40 | 7.32 | 3.28 | 3.15 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,076 | 2,358 | 2,488 | 2,531 | 2,695 | 2,655 | 2,881 | 3,192 | 3,406 | 3,578 | 3,809 | 3,780 | 3,915 |
| Expenses | 1,536 | 1,670 | 1,729 | 1,812 | 1,970 | 1,970 | 2,000 | 2,254 | 2,550 | 2,632 | 2,796 | 2,820 | 2,943 |
| Material Cost | 724 | 756 | |||||||||||
| Change in Inventories | 22 | -56 | |||||||||||
| Purchases of Stock-in-Trade | 448 | 438 | |||||||||||
| Employee Cost | 447 | 479 | |||||||||||
| Other Expenses | 1,143 | 1,199 | |||||||||||
| Operating Profit | 541 | 688 | 759 | 719 | 725 | 685 | 880 | 938 | 855 | 946 | 1,014 | 960 | 972 |
| OPM % | 26 | 29 | 31 | 28 | 27 | 26 | 31 | 29 | 25 | 26 | 27 | 25 | 25 |
| Other Income | 91 | 44 | 31 | 19 | 25 | 46 | 69 | 90 | 69 | 41 | 68 | 75 | 72 |
| Exceptional items (within Other Income) | 0 | -10 | |||||||||||
| Interest | 5 | 54 | 58 | 34 | 21 | 21 | 13 | 5 | 7 | 10 | 9 | 11 | 14 |
| Depreciation | 34 | 255 | 309 | 311 | 325 | 336 | 367 | 335 | 247 | 186 | 178 | 177 | 176 |
| Profit before tax | 592 | 423 | 424 | 393 | 403 | 374 | 569 | 688 | 670 | 791 | 894 | 846 | 854 |
| Tax % | 18 | 14 | 20 | 22 | 25 | 19 | 20 | -22 | 6 | 8 | 10 | 8 | |
| Net Profit | 485 | 363 | 340 | 306 | 303 | 302 | 455 | 837 | 627 | 724 | 803 | 775 | 750 |
| EPS in Rs | 11 | 8 | 7.50 | 6.77 | 6.68 | 6.67 | 10 | 19 | 15 | 17 | 18 | 18 | 17 |
| Diluted EPS in Rs | 18 | 18 | |||||||||||
| Dividend Payout % | 33 | 44 | 47 | 52 | 60 | 60 | 78 | 42 | 55 | 48 | 54 | 56 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 5%
- 5 years
- 6%
- 3 years
- 4%
- TTM
- 3%
Compounded profit growth
- 10 years
- 6%
- 5 years
- 11%
- 3 years
- 5%
- TTM
- -7%
Stock price CAGR
- 10 years
- -4%
- 5 years
- -7%
- 3 years
- -10%
- 1 year
- -31%
Return on equity
- 10 years
- 26%
- 5 years
- 31%
- 3 years
- 28%
- Last year
- 26%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 45 | 45 | 44 | 44 | 44 | 44 | 44 | 44 |
| Reserves | 1,208 | 1,589 | 1,732 | 1,991 | 2,031 | 1,778 | 1,718 | 2,032 | 2,259 | 2,403 | 2,651 | 2,880 |
| Borrowings | 36 | 671 | 473 | 326 | 110 | 210 | 101 | 282 | 91 | 94 | 90 | 162 |
| Other Liabilities | 410 | 409 | 376 | 458 | 633 | 644 | 656 | 692 | 703 | 728 | 741 | 745 |
| Minority Interest | -1.43 | -1.54 | ||||||||||
| Total Liabilities | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,525 | 3,831 |
| Fixed Assets | 453 | 1,918 | 1,994 | 1,802 | 1,680 | 1,459 | 1,132 | 1,344 | 1,245 | 1,114 | 984 | 886 |
| CWIP | 29 | 67 | 22 | 30 | 36 | 8 | 6 | 3 | 6 | 8 | 15 | 1 |
| Investments | 501 | 104 | 128 | 314 | 187 | 156 | 255 | 303 | 293 | 442 | 676 | 834 |
| Other Assets | 693 | 604 | 460 | 652 | 915 | 1,055 | 1,126 | 1,400 | 1,551 | 1,706 | 1,850 | 2,108 |
| Total Assets | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,525 | 3,831 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 534 | 562 | 730 | 588 | 554 | 531 | 922 | 644 | 749 | 779 | 896 | 801 |
| Cash from Investing Activity | -237 | -1,313 | -306 | -276 | -26 | -231 | -224 | -234 | -122 | -210 | -345 | -174 |
| Cash from Financing Activity | -215 | 502 | -496 | -324 | -428 | -405 | -688 | -402 | -608 | -563 | -500 | -554 |
| Net Cash Flow | 82 | -249 | -72 | -12 | 100 | -106 | 9 | 8 | 19 | 6 | 52 | 72 |
| Free Cash Flow | 426 | 430 | 448 | 465 | 421 | 383 | 890 | 164 | 719 | 750 | 852 | 771 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 20 | 14 | 22 | 29 | 42 | 29 | 37 | 44 | 50 | 43 | 33 |
| Inventory Days | 59 | 68 | 83 | 87 | 88 | 102 | 118 | 121 | 100 | 102 | 94 | 128 |
| Days Payable | 90 | 112 | 85 | 109 | 115 | 135 | 138 | 138 | 124 | 143 | 133 | 153 |
| Cash Conversion Cycle | -13 | -24 | 12 | 1 | 2 | 9 | 10 | 19 | 20 | 9 | 4 | 8 |
| Working Capital Days | -16 | -54 | -62 | -32 | -6 | 7 | -3 | 0 | 28 | 30 | 25 | 21 |
| ROCE % | 61 | 30 | 23 | 22 | 19 | 18 | 29 | 31 | 28 | 32 | 32 | 28 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
98,42,622inr
2026-03-31
News
News and filings about Emami Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- HDPE/LDPE & laminate packaging
- Hard paraffin / microcrystalline (MC) wax
- Light liquid paraffin (LLP) — Navratna/BoroPlus base
- Medicinal & aromatic herbs (ashwagandha, tulsi, lemongrass, kaunch, vasak, etc.)
- Menthol / mentha oil
- Methyl salicylate
- Stearic acid / fatty acids
Depends on the price of
- Crude Oil Brent
- Medicinal Herbs
- mentha
Sells to
- Avenue Supermarts Limited · FMCG personal & healthcare products via modern trade
- Reliance Industries · FMCG products via modern-trade / Reliance Retail
- Trent Limited · FMCG products via modern-trade retail
- V-Mart Retail Limited · FMCG products via modern-trade retail
Buys from
- B&B Triplewall Containers Limited · Corrugated packaging
- Galaxy Surfactants Limited · surfactants and specialty ingredients for personal care products
- Gandhar Oil Refinery (India) Limited · White oils / petroleum jelly for personal care (PHPO division)
- Hitech Corporation Limited · rigid plastic personal care packaging (carried forward from the prior pass and not re-name…
- Huhtamaki India Limited · Flexible packaging — laminates, pouches (personal care & healthcare)
- Orissa Bengal Carrier Limited · road transportation / bulk FTL, LTL, parcel and 3PL logistics services
- Shree Rama Multi-Tech Limited · laminated tubes / tube laminates and primary packaging; named on the company website custo…
- Shree Vasu Logistics Limited · CFA, warehousing & 3PL logistics services
- Unicommerce Esolutions Limited · eCommerce enablement SaaS — Uniware (marquee client)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Fast Moving Consumer Goods
- Industry
- Personal Care
- Classification
- Fast Moving Consumer Goods › Personal Care
- ISIN
- INE548C01032
Plants
- Emami Amingaon (Guwahati) unit
- Emami Masat unit
- Emami Pacharia unit
- Emami Pantnagar unit
- Emami Vapi unit
News impact
Big market events that reach Emami Limited, and how the effect spreads.
1 Oct, 10:47 IST · Market event · high impact
Cupid shares hit fresh 52-week high as firm raises FY27 revenue, profit guidance again; multibagger stock skyrockets 617% in a year
Cupid raised FY27 targets to Rs 800 crore sales and Rs 250 crore profit on booming demand, lifting its own shares to a new high while rival consumer-goods makers gain nothing.
Who it hits first
- Cupid raised its FY27 targets for the second time in two weeks, now guiding Rs 800 crore revenue and Rs 250 crore net profit.
- Shares hit a fresh 52-week high, extending a 617% one-year run on strong home and export demand.
- No other company's earnings change: the raise covers Cupid's own orders only.
Who may gain
- Cupid shareholders, who see higher expected earnings and a fresh 52-week high
- Cupid distributors and export partners, if higher volumes flow through their channels
- No peer beneficiary: rival consumer-goods makers gain no sales from Cupid's own targets
Along the supply chain
Downstream
Distributors and export agents handling Cupid's products move higher volumes as the raised targets turn into shipments.
Upstream
Mild upstream pull: if Cupid makes more goods, its raw-material and packaging suppliers see slightly bigger orders.
Where demand moves
Business
Real product demand: buyers at home and abroad are ordering more of Cupid's goods, which is why its targets rose twice in two weeks.
Capital
Growth money chases the raise, bidding Cupid to a 52-week high; peers see no spillover inflows since their earnings are untouched.
How it spreads across sectors
Fast Moving Consumer Goods
Neutral: large consumer-goods makers share no shelf or tender with Cupid's niche, so no sales spill over.
Healthcare
Positive but narrow: one small company's beat lifts sentiment without changing hospital, lab or pharma demand.
When it plays out
Immediate
Cupid extends gains over 1-7 days as the raise sinks in; peers drift with the market.
Medium term
Over 1-6 months Cupid must convert guidance into quarterly numbers; any miss would unwind the premium fast.
Short term
Over 1-4 weeks Cupid consolidates near highs unless buyers keep chasing; profit-booking risk grows after 617%.
29 Sept, 17:34 IST · Market event · high impact
Cupid shares end 10% higher ahead of Nifty Smallcap 250 inclusion tomorrow. How much inflows can it see?
Cupid joins the Nifty Smallcap 250 tomorrow, forcing index funds to buy its shares, which helps Cupid holders but leaves rival personal-care makers untouched.
Who it hits first
- Cupid Limited, a small maker of personal-care and contraceptive goods, jumped 10% to Rs 291 on news that it joins the Nifty Smallcap 250 index from September 30.
- Joining the index means mutual funds and exchange-traded funds that copy that index (called passive funds) must buy Cupid shares, creating a one-off wave of forced buying.
- The stock has already surged 250% in six months, and strong June-quarter results plus higher FY27 guidance give buyers a growth story beyond the index news.
- No factory, order, or sales change is involved — this is purely a money-flow event, not a business event.
Who may gain
- Cupid's existing shareholders, who gain as forced index buying pushes the share price up.
- Cupid Limited itself, which gets more visibility and easier future fundraising as an index stock.
- Short-term traders who bought before the announcement and can sell into the passive demand.
Along the supply chain
Downstream
No direct supply-chain link downstream — distributors and retailers see no change in product flow from a stock-market event.
Upstream
No direct supply-chain link upstream — index inclusion does not change Cupid's raw-material or packaging orders.
Where demand moves
Business
No change in business demand — shops do not order more Cupid products because the stock joined an index; sales depend on the June-quarter momentum and guidance, not the listing.
Capital
Positive capital demand for Cupid only — passive funds that copy the Nifty Smallcap 250 must buy the stock around September 30, and active traders front-running that bid amplified the 10% pre-move.
How it spreads across sectors
Fast Moving Consumer Goods
Neutral for peers — Godrej Consumer, Dabur, Emami, Colgate and other personal-care makers get no order or money-flow spillover from Cupid's inclusion.
Healthcare
Negligible — a single-stock index-flow event with no change in healthcare demand, pricing, or regulation.
When it plays out
Immediate
September 30 inclusion day: forced passive buying, high volume, and a choppy price as pre-positioned traders sell into the index bid.
Medium term
1–6 months: index status stops mattering; only earnings delivery against the raised guidance and the stretched valuation decide the path.
Short term
1–4 weeks: tracking settles, the index premium fades, and the price drifts on profit-taking versus the FY27 guidance story.
29 Sept, 10:17 IST · Market event · high impact
Honasa Consumer Share Price Falls Over 3% On Block Deal Buzz
Early investors plan to sell up to 89 lakh Honasa shares in a block deal, so Honasa shares fell over 3%, hurting current holders while block buyers may get a discount and rivals see no change.
Who it hits first
- Honasa Consumer, which sells Mamaearth beauty and baby-care products, fell over 3% after news that early backers may sell up to 89 lakh shares in one block trade.
- Peak XV Partners, Sequoia Capital Global Growth Fund III and Redwood Trust are the likely sellers, cashing out part of their early stake.
- A big sale like this adds many shares for sale at once, so the price dips until new buyers absorb the block.
Who may gain
- Block-deal buyers, who may pick up Honasa shares at a discount to the market price
- Short-term traders who sold early on the buzz and can buy back lower after the sale
- Patient buyers who want Honasa for its brands and get a cheaper entry on the dip
Along the supply chain
Downstream
No downstream change — Nykaa, the beauty retailer that sells Honasa products, sees the same shopper demand; only Honasa's share price moves.
Upstream
No upstream change — software and order-service providers to Honasa see no order change when investors sell shares.
Where demand moves
Business
No change in shop demand — people buy the same Mamaearth creams and shampoos; only share ownership changes hands.
Capital
Selling pressure on Honasa shares — up to 89 lakh shares offered in the block must find new buyers, so the price slips until the block clears.
How it spreads across sectors
Fast Moving Consumer Goods
No real ripple — a single-company share sale does not change soap, cream or shampoo sales for Dabur, Godrej Consumer, Emami or Colgate.
When it plays out
Immediate
In 1-7 days, Honasa stays weak as the 89-lakh-share block hangs over the price and clears.
Medium term
In 1-6 months, price follows business — Mamaearth growth and profits matter, not the old investor exit.
Short term
In 1-4 weeks, shares steady once the block finds buyers and focus returns to sales and margins.
15 Sept, 05:00 IST · Market event · medium impact
Emami board to consider share buyback on September 17
Ayurveda products maker Emami may announce buying back its own shares on September 17 — usually a quick boost for the stock.
Who it hits first
- Emami stock rallies 2-4% into the Sep-17 board meet on buyback expectations.
- A confirmed buyback shrinks share count and lifts per-share earnings and price.
- FMCG peers see no fundamental impact — pure sentiment markers.
Who may gain
- Emami shareholders: buyback price support plus reduced share count.
Along the supply chain
Downstream
Distributors and retailers see zero impact from a board buyback decision.
Upstream
No direct supply-chain link — a capital-allocation event, not an operations event.
Where demand moves
Business
No business-demand change — this is capital return, not operations; traders supply event liquidity.
Capital
Money rotates into Emami for the event; record-date arbitrage follows if confirmed.
How it spreads across sectors
Fast Moving Consumer Goods
No ripple — single-company capital return with no peer read-through.
When it plays out
Immediate
Emami up 2-4% into Sep 17; peers flat.
Medium term
Executed buybacks support the price for quarters via a smaller share count.
Short term
Board decision day decides all: confirm (rally extends) or defer (full unwind).
19 Jun, 04:22 IST · Market event · medium impact
L'Oreal acquires majority stake in Innovist, parent of D2C beauty brand Bare Anatomy
Who it hits first
- HONASA: HONASA (Mamaearth): direct listed D2C beauty competitor faces sharper L'Oreal heat. PE 65.1 >> FMCG median 25.7 (premium); ROE 15.7 above 11.4; pledge 4.2%.
Who may gain
- HINDUNILVR: HUL premium beauty validation. PE 33.5 above FMCG median 25.7; ROE 31.0 well above 11.4. Lakme/Dove portfolio benefits from category premiumisation.
- DABUR: DABUR ayurvedic + beauty portfolio. PE 39.7 above FMCG median 25.7; ROE 17.2 above 11.4.
- EMAMILTD: EMAMI premium personal care exposure. PE 25.0 at FMCG median 25.7; ROE 30.2 well above 11.4.
Along the supply chain
Downstream
NYKAA distribution channel benefits from Innovist brand growth; e-commerce volume growth; influencer/MarTech (AFFLE) benefits from increased beauty ad spend.
Upstream
Specialty chemicals (FINEORG, AARTIIND) and fragrance ingredient makers benefit from L'Oreal scaling Innovist with global supply chain.
Where demand moves
Business
L'Oreal majority in Innovist (Bare Anatomy) intensifies premium D2C beauty competition. HONASA Mamaearth faces direct pressure. NYKAA dual-edged: category growth positive, brand-side competition negative. Listed FMCG (HUL, DABUR, EMAMI) gain category premium validation.
Capital
Capital flows into premium beauty validation names — NYKAA, HONASA mixed; HUL premium-beauty exposure (Lakme, Dove, Pond) gets re-rating support. D2C-focused specialty chemicals (FINEORG, CLEAN) may see investor interest.
How it spreads across sectors
Beauty & Personal Care
M&A premium for D2C beauty assets
D2C
Exit liquidity validated — early-stage VCs see clearer exit pathway
FMCG
D2C premium beauty acquisition validates HUL, DABUR Vatika premium bet
codex additions
Commodity angle
Cc skip reason
no_commodity_link
When it plays out
Immediate
HONASA -3-5% on competitive intensity; NYKAA mixed (+/-1-2%); HUL, DABUR +1-2% sympathy.
Medium term
India premium beauty TAM doubles 2026-2028; consolidation cycle continues with more global PE/strategic interest.
Short term
Q1FY27 D2C beauty commentary will reveal L'Oreal-Innovist's pricing strategy — sustained re-rating or fade.
Other sectors it reaches
- {"causal_chain":"Premium beauty consolidation raises demand for differentiated actives, surfactants, aroma chemicals, preservatives and formulation inputs as large strategics scale acquired D2C brands.","direction":"positive","example_tickers":["FINEORG","AARTIIND","CLEAN"],"magnitude":"medium","notes":"Benefit is indirect and depends on domestic sourcing versus imported formulations.","sector":"Specialty Chemicals \u0026 Fragrance Ingredients","time_horizon":"1_to_6_months"}
- {"causal_chain":"Beauty and personal-care premiumization increases need for tubes, pumps, labels, cartons, rigid plastics and sustainable packaging as brands upgrade shelf appeal and omnichannel formats.","direction":"positive","example_tickers":["UFLEX","HUHTAMAKI","EPL"],"magnitude":"medium","notes":"EPL has direct relevance through laminated tubes used in oral care, beauty and personal care.","sector":"Packaging","time_horizon":"1_to_6_months"}
- {"causal_chain":"Global FMCG buyers acquiring Indian D2C brands may outsource incremental production before investing in captive capacity, lifting demand for third-party formulation and manufacturing partners.","direction":"positive","example_tickers":["HINDUNILVR","GODREJCP","JYOTHYLAB"],"magnitude":"small","notes":"Few pure-play listed beauty contract manufacturers exist on NSE, so tickers are imperfect proxies through consumer manufacturing exposure.","sector":"Contract Manufacturing / CDMO for Consumer Products","time_horizon":"1_to_6_months"}
- {"causal_chain":"Strategic validation of D2C beauty increases paid discovery, marketplace launches, brand-store investments and online assortment expansion across premium personal care.","direction":"positive","example_tickers":["NYKAA","INDIAMART","MSTCLTD"],"magnitude":"medium","notes":"NYKAA is mixed: competitive pressure from L'Oreal-controlled brands, but category traffic and GMV validation are supportive.","sector":"E-commerce Marketplaces \u0026 Online Retail Enablement","time_horizon":"immediate"}
- {"causal_chain":"Beauty D2C brands rely heavily on influencer marketing, performance ads, CRM and content commerce; acquisition-driven competition can raise customer-acquisition spending across the category.","direction":"positive","example_tickers":["AFFLE","NAZARA","TIPSFILMS"],"magnitude":"small","notes":"Listed proxies are broad digital media/ad-tech plays rather than beauty-specific vendors.","sector":"Digital Advertising \u0026 MarTech","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Premium beauty brands compete through creator-led education, celebrity collaborations, reels, tutorials and launch campaigns, increasing spend on digital content and influencer ecosystems.","direction":"positive","example_tickers":["SAREGAMA","TIPSINDLTD","ZEEL"],"magnitude":"small","notes":"Impact is diffuse and more visible in campaign activity than near-term earnings.","sector":"Media, Influencer \u0026 Entertainment Platforms","time_horizon":"1_to_4_weeks"}
- {"causal_chain":"Scaling D2C beauty requires faster fulfillment, returns handling, marketplace warehousing and cold/controlled storage for certain formulations, supporting third-party logistics demand.","direction":"positive","example_tickers":["DELHIVERY","TCI","BLUEDART"],"magnitude":"small","notes":"Beauty is a small share of total logistics volumes, but high SKU complexity makes the category operationally relevant.","sector":"Logistics \u0026 Warehousing","time_horizon":"1_to_6_months"}
- {"causal_chain":"D2C beauty brands that receive strategic backing often move from online-only to omnichannel kiosks, shop-in-shops and mall stores, lifting demand for premium retail space.","direction":"positive","example_tickers":["PHOENIXLTD","PRESTIGE","DLF"],"magnitude":"small","notes":"More relevant for premium malls and high-street retail than broad real estate.","sector":"Retail Real Estate / Malls","time_horizon":"1_to_6_months"}
- {"causal_chain":"Large FMCG-led acquisitions validate consumer-brand M\u0026A, potentially increasing deal financing, advisory mandates, founder liquidity and wealth-management flows.","direction":"positive","example_tickers":["ICICIBANK","KOTAKBANK","AXISBANK"],"magnitude":"small","notes":"Likely modest unless it triggers a broader consumer D2C transaction cycle.","sector":"Private Banks \u0026 Investment Banking / Wealth","time_horizon":"1_to_6_months"}
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 10 Feb 2026 | interim | ₹6 |
|---|---|---|
| 14 Nov 2025 | interim | ₹4 |
| 22 May 2025 | special | ₹2 |
| 4 Feb 2025 | interim | ₹4 |
| 18 Nov 2024 | interim | ₹4 |
| 16 Feb 2024 | interim | ₹4 |
| 15 Nov 2023 | interim | ₹4 |
| 13 Feb 2023 | interim | ₹4 |
Splits, bonuses & buybacks
- daily-prices repair: 14 rows from NSE's archive (replace 6, delete 1, insert 7), 2016-02-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Feb 2016
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY274 Aug 2026
- Annual report · 2025-2630 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2621 May 2026
- Earnings call · Q3FY264 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.